Evidence mapPaperPMID 41532552Full record

ArticleJournal of the American Heart Association2026

Heart Failure Risk in Patients With Systemic Autoimmune Inflammatory Diseases.

Alexia A Zagouras, Pieter Martens, W H Wilson Tang

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexia A ZagourasDepartment of Internal Medicine Stanford University School of Medicine Stanford CA USA.
Pieter MartensZiekenhuis Oost Limburg Genk Belgium.
W H Wilson TangKaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio USA.ORCID 0000-0002-8335-735X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac disease, including heart failure (HF), is a significant cause of morbidity and mortality for patients with systemic autoimmune inflammatory diseases (SAIDs). We sought to describe HF risk among patients with SAIDs and to investigate associations between cardiovascular drug use and incident HF.

methodsWe conducted a retrospective cohort study of electronic health records of 182 795 adult patients with SAIDs including systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and HIV from 2000 to 2020 and track their risks of new-onset incident HF in a large multidisciplinary health care institution.

resultsSystemic sclerosis (adjusted hazard ratio [aHR], 2.81 [95% CI, 2.57-3.08];

conclusionsPatients with systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis had increased risk of incident HF independent of traditional risk factors, indicating an underlying autoimmune mechanism of cardiac involvement. Beta-blocker use was associated with decreased incident HF, indicating a potentially cardioprotective effect in SAIDs.

Indexed as

Autoimmune DiseasesHeart FailureAdrenergic beta-AntagonistsAdultAgedArthritis, RheumatoidFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsAdrenergic beta-Antagonistsbeta blockerheart failuresystemic autoimmune inflammatory diseases

Identifiers

PMID41532552
PMCPMC12919521

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.